The estimated Net Worth of Michael Vangsted Jensen is at least $66.3 millier dollars as of 3 April 2023. Mr Jensen owns over 2,553 units of Synlogic Inc stock worth over $64,787 and over the last 3 years he sold SYBX stock worth over $1,481.
Mr has made over 2 trades of the Synlogic Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 2,553 units of SYBX stock worth $1,481 on 3 April 2023.
The largest trade he's ever made was buying 9,500 units of Synlogic Inc stock on 24 May 2022 worth over $10,640. On average, Mr trades about 3,013 units every 79 days since 2022. As of 3 April 2023 he still owns at least 46,947 units of Synlogic Inc stock.
You can see the complete history of Mr Jensen stock trades at the bottom of the page.
Michael Jensen is the Chief Financial Officer at Synlogic Inc.
Michael's mailing address filed with the SEC is C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE, MA, 02142.
Over the last 7 years, insiders at Synlogic Inc have traded over $330,991 worth of Synlogic Inc stock and bought 17,000 units worth $31,190 . The most active insiders traders include Forest Baskett, Scott D Sandell et Anthony A. Jr. Florence. On average, Synlogic Inc executives and independent directors trade stock every 132 days with the average trade being worth of $7,257. The most recent stock trade was executed by Mary Beth Dooley on 2 April 2024, trading 188 units of SYBX stock currently worth $325.
at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre
Synlogic Inc executives and other stock owners filed with the SEC include: